Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132617) titled 'An open-label, multicenter study of MRG001 combined with Lenalidomide/ Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)' on Sept. 16.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Henan Cancer Hospital
Condition:
R/R DLBCL
Intervention:
Group 1:MRG001 combined with 15mg Lenalidomide
Group 2:MRG001 combined with 20mg Lenalidomide
Recruitment Status: Not Recruiting
Phase: 0
Date of First Enrollment: 2024-07-02
Target Sample Size: Group 1:30;Group 2:30;Group 3:30;
Countries of Recruitment:
China
To know more, vi...